Skip to main content
. 2026 Feb 16;18(4):642. doi: 10.3390/cancers18040642
CI Confidence interval
CIt Cumulative incidence for interval t
CM Cutaneous melanoma
CsA Cyclosporine A
CNI Calcineurin inhibitor
GS Glucocorticosteroids
IFN-γ Interferon gamma
IL-2 Interleukin 2
IL-4 Interleukin 4
IRt Incidence rate for interval t
MPA Mycophenolic acid (administered as mycophenolate mofetil [MMF] or mycophenolate sodium [MPS])
NF-AT Nuclear factor of activated T cells
NMSC Non-melanoma skin cancer
PNCR Polish National Cancer Registry
PNHF Polish National Health Fund
RD Risk difference
RR Relative risk
SIR Standardized incidence ratio
TAC Tacrolimus
TNF-α Tumor necrosis factor alpha